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Highlights 
- Synaptic changes occur early in most neurodegenerative diseases. 
- Synaptic changes likely contribute to cognitive decline in ageing. 
- Targeting synaptic pathology is a promising therapeutic strategy. 
 
 
  
 Abstract 
Synaptic proteomes have evolved a rich and complex diversity to allow the exquisite 
control of neuronal communication and information transfer. It is therefore not 
surprising that many neurological disorders are associated with alterations in synaptic 
function. As technology has advanced, our ability to study the anatomical and 
physiological function of synapses in greater detail has revealed a critical role for both 
central and peripheral synapses in neurodegenerative disease. Synapse loss has a 
devastating effect on cellular communication, leading to wide ranging effects such as 
network disruption within central neural systems and muscle wastage in the 
periphery. These devastating effects link synaptic pathology to a diverse range of 
neurological disorders, spanning Alzheimer’s disease to multiple sclerosis. This 
review will highlight some of the current literature on synaptic integrity in animal 
models of disease and human post-mortem studies. Synaptic changes in normal brain 
ageing will also be discussed and finally the current and prospective treatments for 
neurodegenerative disorders will be summarised. 
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Introduction 
The approximately one hundred billion neurons found within the human brain act in 
beautifully intricate arrangements to generate and control our every thought, memory, 
emotion and dream. They also control our ability to sense the world, to communicate 
those sensations to others and decide how to plan our lives. These remarkable abilities 
are only possible if neurons can efficiently coordinate with other cells in the network, 
and the transfer of information occurs at specialised compartments called synapses 
(Figure 1). 
 
Depending on the chemical signal released, synapses can have excitatory or inhibitory 
effects on the target cell. Excitatory synapses most commonly form on small dendritic 
protrusions known as spines, where the synapse can be isolated from the main 
dendritic branch and become highly specialised. Inhibitory synapses tend to form 
directly onto the dendritic branch or onto the neuronal cell soma, although some 
exceptions to this general rule do occur. Once formed, these synaptic contacts are not 
rigid and can strengthen in response to increased activity or become shrunken and 
even lost following lack of activity [1]. This plasticity is thought to play a 
fundamental role in the formation, storage and removal of memory [2]. Furthermore, 
spine dynamics can often be used as a quantifiable means of analysing circuit activity 
as spine number and morphology change in response to fluctuations in neuronal 
activity [1]. See Figure 1D for a summary of this concept. 
 
Given the critical role synapses play in normal neurophysiology, it is not surprising 
that loss of synaptic integrity may underlie many of the most common 
neurodegenerative diseases. Synaptic dysfunction or synaptic loss often precedes late-
stage features of many neurological conditions such as Alzheimer’s disease [3], 
Motor Neuron disease [4, 5], Huntington’s disease [6], Parkinson’s disease [7, 8] and 
multiple sclerosis [9]. While synaptic pathology is a common feature of these 
disorders, the nature of the synaptic change is not necessarily consistent, which 
illustrates how critical normal neuronal function is for brain health. Given the 
plasticity of synapses and the malleability of dendritic spines, it raises the possibility 
of exploiting these features as potential therapeutic targets. If we can prevent synaptic 
loss or strengthen existing connections between neurons, we may be able to slow or 
even reverse disease-driven neurological change.  
 
In this review, we will highlight a selection of neurodegenerative disorders that 
exhibit synaptic dysfunction as an early feature of the disease, discuss the changes 
that occur during normal brain ageing and discuss the current and prospective ways in 
which synaptic function can be targeted for therapeutic exploitation. 
 
Synapse Structure 
Synapses are the point of contact between two neurons and can exist as either 
electrical or, more often, chemical synapses. In both cases the cells don’t touch, but 
communicate by passing ions (electrical synapse) or neurotransmitters (chemical 
synapse) across a small gap known as the synaptic cleft. Adhesion proteins such as 
neuroligins and neurexins span this cleft, physically holding the synapse in place [10] 
(Figure 1C). Intriguingly, these cleft-spanning proteins are critical for synaptic 
integrity and mutations in the genes for these proteins have been implicated in 
neurological disorders [10]. 
 
The presynaptic bouton contains the complex machinery required for synthesis, 
storage and release of neurotransmitters [11] (Figure 1C). This is a tightly regulated 
process, ensuring efficient and accurate transmitter release following action potential 
propagation. Synaptic vesicles, packed with neurotransmitter, undergo calcium-
dependent fusion with the presynaptic membrane and release their contents into the 
synaptic cleft. Altered protein homeostasis in the presynaptic terminal has been linked 
to neurological disorders. The abundant presynaptic protein alpha-synuclein forms 
striking pathological aggregates in a group of neurological disorders known as 
synucleinopathies [12]. 
 
Once released from the presynaptic terminal, neurotransmitters cross the synaptic 
cleft and interact with receptors in the postsynaptic membrane. Ligand-gated ion 
channels (ionotropic receptors) open rapidly upon neurotransmitter binding and allow 
the direct flow of ions into the postsynaptic neuron, altering the local membrane 
potential. G-protein coupled receptors (GPCRs; metabotropic receptors) induce an 
array of downstream signalling cascades following neurotransmitter binding, which 
are important for local protein homeostasis and dendritic spine morphology (Figure 
1C). 
 
The receptors are held in place by a vast protein scaffold known as the postsynaptic 
density (PSD), which contains almost 1500 proteins [13] and can be seen as an 
electron-dense structure under the electron microscope (Figure 1B). Disruptions of 
this critical protein scaffold can have severely detrimental effects on synaptic 
function, and altered expression of PSD proteins are a common feature of many 
neurological disorders [13]. Figure 1 shows an example of a typical excitatory 
synapse with some important proteins highlighted. 
 
In summary, to ensure efficient information transfer between neurons, the synapse 
must be anatomically intact. Disruptions in synaptic composition can have severe 
effects on synaptic function, leading to altered network activity and ultimately the 
clinical manifestation of disease. 
 
Alzheimer’s Disease 
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder exhibiting 
striking brain atrophy.  The brains of AD patients contain two definitive hallmarks of 
the disease, insoluble beta-amyloid plaques and hyperphosphorylated-tau positive 
tangles. Plaques are formed extracellularly by the deposition of insoluble amyloid 
beta peptides, whereas the neurofibrillary tangles are found intracellularly as long tau 
fibrils characteristically tangled around the nucleus in neuronal cell soma. Neurons 
and synapses are progressively lost during the disease in tandem with the spread of 
tau pathology through the brain [14].  However, the early clinical manifestations of 
memory impairment are likely due to synapse dysfunction and loss rather than to 
neuron loss or the accumulation of plaques and tangles. A large amount of evidence 
suggests that the fibrillar plaques and neurofibrillary tangles are not in themselves 
toxic.  These lesions are often found in cognitively normal aged brains [15-17].  The 
strongest pathological correlate with cognitive change is synapse loss [18], suggesting 
that the loss of synapses is sufficient to drive AD-related cognitive decline, before the 
loss of neurons [3, 19]. What causes the synaptic loss is yet to be fully elucidated but 
it appears that both soluble amyloid and soluble tau have a role to play [20]. In mouse 
models of amyloid pathology and human post-mortem tissue, synapses are 
predominantly lost around mature, dense-core amyloid plaques [21, 22]. Interestingly, 
there is no increased synapse loss in or around diffuse plaques, which don’t appear to 
affect the surrounding neuropil and are made up of small scattered bundles of amyloid 
fibrils [23]. This may suggest that dense-core amyloid plaques release synaptotoxic 
molecules in their vicinity. In support of this idea, work in transgenic mouse models 
revealed a halo of oligomeric amyloid around the edge of plaques and some of this 
soluble amyloid is found within synapses [21, 22], as independently observed using 
electron microscopy [24]. The presence of soluble amyloid in the synapse appears to 
drive shrinkage and ultimately loss of that connection perhaps through microglial-
mediated mechanisms regulated by C1q and complement 3 [25]. Before synapses are 
lost synaptic function is significantly disrupted by the presence of soluble amyloid. 
Mouse models have shown that the application of synthetic amyloid species results in 
impaired LTP [26, 27] and enhanced LTD [28], ultimately weakening the synapse. 
These effects are due to the dysregulation of numerous signalling pathways, but it is 
evident that the synaptic AMPA [29] and NMDA [30] receptors play a critical role. 
LTP causes an increase in spine size and requires high calcium levels within the 
spine, as a result of rapid influx through NMDA receptors [31]. LTD causes spine 
shrinkage, as a result of a slower influx through NMDA receptors and ultimately a 
lower level of calcium in the spine [32]. Oligomeric amyloid can bind NMDA 
receptors and block NMDA-evoked currents resulting in slower calcium dynamics, 
which favours the induction of LTD in the spine [33]. Furthermore, the effect of 
numerous kinases within the spine critical for LTP induction such as JNK [34], p38 
MAPK [34] and CaMKII [35, 36] can be altered by oligomeric amyloid. Also, the 
calcium-dependent phosphatase Calcineurin is activated by amyloid [37], leading to 
the internalisation of AMPA [37, 38] and NMDA [33] receptors away from the 
synapse, leading to the loss of synapses and spines. This synapse-specific loss of 
NMDA receptors is important in a number of ways. Firstly, it reduces excitatory 
synaptic activity leading to synapse weakening and secondly, it leads to a change in 
the balance of synaptic and extra-synaptic signalling. Synaptic NMDA receptors are 
thought to induce pro-survival signalling pathways, whereas NMDA receptors outside 
the synapse (extrasynaptic) promote toxic, cell-death pathways [39], therefore a loss 
in synaptic signalling will lead to a greater influence of toxic, extrasynaptic 
signalling. It has been shown in cultured mouse cortical neurons and in synaptic/non-
synaptic fractions of homogenized mouse hippocampal slices that extrasynaptic 
NMDA receptor levels are not changed following amyloid-β treatment, whereas 
synaptic levels significantly decrease [33, 40]. Therefore, amyloid-β may induce 
synapse loss via a combination of synaptic weakening and a shift towards toxic 
extrasynaptic signalling. Another way in which amyloid-β may significantly alter 
synaptic function is by disrupting mitochondrial physiology. Mitochondria are critical 
for maintaining the high-energy supply required for efficient synaptic function and it 
is thought that mitochondrial dysfunction plays an important role in AD pathogenesis 
[41]. For example, a recent study has found a direct molecular link between amyloid-
β and Abeta-binding alcohol dehydrogenase (ABAD), leading to mitochondrial 
dysfunction, oxidative stress and cell death [42]. 
 
Intriguingly, a very recent study utilising human tissue and rodent models has shown 
that amyloid binds to and disrupts an adhesion protein that spans the synaptic cleft 
and holds the synapse in place. The authors suggest that amyloid-dependent 
breakdown of NCAM2 leads to synapse disassembly [43]. 
 
The role of tau in synapse loss is less well established. Tau is a microtubule binding 
protein which during the course of AD becomes hyperphosphorylated and 
accumulates in neuronal somata and dendrites [44]. Despite the historical belief that 
tau is confined to the axon, recent studies have revealed an important role for tau in 
the PSD [45]. Furthermore, imaging studies have revealed the abnormal accumulation 
of tau in spines from both mouse models and human AD post-mortem tissue [46-49]. 
Given the important role tau plays in microtubule stabilisation and subsequent protein 
trafficking, it is easy to imagine that pathological tau dislocation would result in failed 
trafficking of critical proteins required for synaptic function. In support of this, it has 
been shown that expression of hyperphosphorylated tau disrupts the trafficking of 
glutamate receptor subunits [50, 51]. Furthermore, mitochondrial transport is 
significantly disrupted when tau is overexpressed, resulting in disrupted ATP 
production and calcium buffering, and altered mitochondrial distribution in tau over-
expressing neurons in transgenic mice and post-mortem AD brain [49, 52, 53].  
 
Intriguingly, the spread of phosphorylated tau follows a remarkably predictable 
pattern throughout the brain. Abnormal deposits of tau first appear in the 
transentorhinal region before spreading into the nearby entorhinal cortex [54]. The 
pathological spread then appears to follow the flow of synaptic connections from the 
entorhinal cortex into the hippocampus and then from there, out into other cortical 
and subcortical regions [54]. This predictable spread of pathology has led some to 
believe that phosphorylated tau is passed between neurons that are synaptically 
connected [55-58]. However, the route of transmission and the identity of the 
propagating toxic tau species are yet to be fully elucidated [59, 60]. Research is now 
beginning to focus on potential synergistic or hierarchical effects of amyloid and tau 
in synapse loss [20]. One interesting potential link between amyloid-β and tau 
pathology is the finding that specific activation of extrasynaptic NMDA receptors 
enhances tau phosphorylation in cultured mouse hippocampal neurons [61]. This may 
suggest that amyloid-β not only induces synaptic dysfunction, but drives tau 
pathology via extrasynaptic NMDA receptor signalling.  Treating primary neurons 
with physiological concentrations of amyloid-β induces synapse loss, which has 
recently been associated with tau mislocalization to dendrites [62].  Further, 
genetically removing endogenous mouse tau prevents some of the synaptic deficits 
associated with overexpressing mutant amyloid [63, 64]. 
 
In summary, the vulnerability of synapses in AD is striking and is supported by a vast 
literature describing presynaptic, postsynaptic and even trans-synaptic sites of damage 
following the generation of pathological species of amyloid and tau.  
 
α-synucleinopathies: Parkinson’s disease and Dementia with Lewy Bodies 
Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) belong to a group of 
neurodegenerative disorders called α-synucleinopathies. Patients’ brains contain 
pathological aggregates of the presynaptic α-synuclein protein, which can exist as 
neuronal cytoplasmic aggregates called Lewy bodies or longer fibril-like structures in 
the neuronal processes, known as Lewy neurites. Aggregates can also be found in 
glial cells in other α-synucleinopathies, such as multiple system atrophy. It is 
currently unknown why this protein leaves the synapse, or why it aggregates. 
 
The loss of dopaminergic neurons in the substantia nigra causing a dramatic reduction 
of striatal dopamine release leads to the clinical motor problems (rigidity, tremor, 
bradykinesia, freezing and postural instability) which are characteristic of PD [65]. 
However, pathology is not restricted to the substantia nigra, as evidenced by a number 
of other non-motor clinical symptoms such as constipation, hyposmia, depression and 
sleep disturbance [66]. In PD it is proposed that the presence of Lewy bodies begins 
before overt clinical symptoms as evidenced by the widely reported incidental Lewy 
body disease (iLBD). The hypothesis put forward by Heiko Braak states that Lewy 
bodies spread in a predictable pattern from the brainstem to subcortical structures and 
finally throughout the cortex in severe late stage cases [67]. Whether Lewy body 
formation is a result or cause of neuronal degeneration is a matter of debate, although 
the progression and severity of disease appears to follow their presence [68].  
 
DLB is a common form of dementia, following Alzheimer’s disease, vascular 
dementia, and mixed AD/vascular dementias in prevalence. The classical core 
features of DLB include fluctuating cognitive impairment with loss of attention and 
executive function, visual hallucinations and Parkinson’s-like motor problems 
(rigidity, tremor, bradykinesia, freezing and postural instability) [69]. As in PD, the 
loss of neurons in the nigrostriatal pathway can account for the motor symptoms 
observed in DLB, yet the number and location of cortical Lewy bodies in DLB don’t 
necessarily track with the severity of disease [69]. However, high incidence of Lewy 
bodies in the anterior and inferior temporal lobe, which is important for forming 
complex visual images, does associate with the presence of visual hallucinations [69]. 
 
In both PD and DLB the severe brain degeneration observed post-mortem cannot be 
explained purely by the presence of Lewy bodies and alternative factors likely play a 
role. One alternative is that small synaptic α-synuclein inclusions may drive a loss of 
synapses in the brain of patients. Indeed, loss of excitatory synapses in the striatum 
has been described in animal models of PD and in human post-mortem brain [7, 70-
72]. Using a PET blot technique, a sucrose gradient fractionation technique and 
electron microscopy, one group have suggested that up to 90% of aggregated α-
synuclein exists in small presynaptic inclusions rather than large somatic Lewy 
bodies, in PD and DLB brains [73, 74]. In DLB cases, this associated with a 
significant decrease in the levels of presynaptic proteins such as synaptophysin. 
Furthermore, filled neurons in DLB brain had significantly fewer dendritic spines, 
corresponding with a decrease in synaptic levels of PSD95. In an α-synuclein 
overexpressing mouse model of DLB, significant loss of presynaptic terminals are 
observed in the hippocampus at 8 months, a few months after α-synuclein aggregates 
begin to appear [75]. However, when the overexpressing transgene was later switched 
off, the synapse loss was reversed and the α-synuclein pathology cleared. 
 
Vesicular monoamine transporter 2 (VMAT2) and the dopamine transporter (DAT) 
are important for the vesicular storage of dopamine in the presynaptic terminal and 
studies have shown a significant reduction in levels and activity of these in human PD 
[76, 77]. Importantly, these proteins appear to inversely correlate with the level of α-
synuclein in the substantia nigra suggesting that increased α-synuclein deposition 
leads to decreased levels of VMAT2 and DAT [77]. In support of a presynaptic 
dysfunction in Parkinson’s, mouse models of the disease exhibit a redistribution of 
numerous critical presynaptic proteins to sites of aggregated α-synuclein, resulting in 
reduced dopamine release in the striatum [78]. Human brain imaging has reinforced 
the case for synaptic failure in PD pathology and has revealed presynaptic disruption 
of numerous neurotransmitter systems [79].  
 
Despite the growing literature describing presynaptic dysfunction in PD, it is clear 
that other synaptic compartments can be affected. For example, exogenously applied 
oligomers of α-synuclein to rat hippocampal slices can disrupt LTP via postsynaptic, 
NMDA receptor-dependent mechanisms [80], and in cultured dopaminergic neurons, 
application of α-synuclein to the culture media leads to internalisation of NMDA 
receptors [81]. In cultured hippocampal neurons, α-synuclein also internalises NMDA 
receptors and affects NMDA-induced Ca
2+
 changes, leading to decreased NMDA-
dependent currents [82]. Given the importance of these receptors in synaptic 
signalling and spine morphogenesis, it is no surprise to find in human post-mortem 
tissue and numerous models of PD that spine densities are altered [83, 84]. 
Furthermore, postsynaptic calcium disruption has been shown in striatopallidal 
medium spiny neurons, leading to rapid loss of glutamatergic axospinous synapses 
and disconnection of the motor system [7]. 
 
It is also clear that mitochondrial dysfunction plays a prominent role in PD and DLB 
pathogenesis and may explain some of the synaptic deficits. Some of the known genes 
associated with familial PD play important roles in normal mitochondrial function, 
such as PINK-1 and Parkin [85]. Also, in numerous model systems, over-expression 
of mutated human α-synuclein can lead to mitochondrial degeneration [86, 87]. 
Furthermore, one of the most common models of PD is the MPTP-induced 
breakdown of dopaminergic neurons and this neuronal death occurs due to inhibition 
of mitochondrial complex I, resulting in massive reactive oxygen species 
accumulation and mitochondrial damage [88, 89]. In DLB post-mortem tissue it has 
been shown that there is a significant loss of mitochondria from neuronal processes, 
with aggregation of mitochondria around cytoplasmic Lewy bodies [90]. Furthermore, 
once the mitochondria are engulfed by the expanding Lewy body their membranes 
rupture and the mitochondria are destroyed [90]. In both PD and DLB, mitochondrial 
dysfunction will hamper energy supply to synapses and this may be a driving force in 
synaptic disconnection. 
 
The overall picture emerging from the current literature is that synaptic pathology is 
an early feature of PD and DLB and that α-synuclein aggregation and deposition can 
affect the synapse both pre- and post-synaptically. This assault from both sides of the 
synapse leads to significant neurophysiological disruption and subsequent anatomical 
change, resulting in spine alterations which affect overall neuronal function and 
circuit activity, leading to neuronal death and clinical manifestation. 
 
Motor Neuron Disease 
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron 
disease and is characterised by the loss of upper and lower motor neurons. This leads 
to progressive muscle weakness and atrophy, and the denervation of respiratory 
muscles is often the cause of death, commonly occurring within 5yrs of diagnosis 
[91]. Catastrophic motor neuron loss represents the final step in disease progression, 
however mounting evidence suggests that synaptic disconnection at the 
neuromuscular junction occurs prior to cell death [4, 5, 92]. This has led to the “dying 
back” hypothesis of disease progression, which states that following toxic insult at the 
neuromuscular synapse, the axon disconnects from the target muscle, leading to 
axonal degeneration and finally neuronal death. Both cell autonomous and non-
autonomous factors have been suggested as the initiating insult [91]. Betz cells are 
giant pyramidal cells residing in layer five of the motor cortex and project directly 
onto the lower motor neurons in the spinal cord. Research has shown that synaptic 
terminals on the soma of normal-looking Betz cells in ALS patients appear 
dysmorphic and exhibit a degenerative appearance [93]. Loss of synaptic input may 
contribute to the dysfunction and loss of these critical cells in muscle control. Recent 
studies using ALS mouse models have revealed that cortical synapse loss may be an 
early presymptomatic feature of ALS. Presymptomatic spine loss was observed in the 
motor cortex of the hSOD1
G93A
 transgenic model [94] and an early shrinkage/loss of 
synapses was observed in the sensorimotor cortex of the FUS-R521C mouse [95]. 
Furthermore, disconnection of the upper and lower motor neuron circuit appears to be 
supported by a loss of synapses onto lower motor neurons in the ventral horn of the 
spinal cord [96-98].  
 
Although the source of the synaptotoxic insult has yet to be fully elucidated, 
interestingly, as described above for Alzheimer’s and Parkinson’s disease, protein 
aggregates also feature in the neuropathology of motor neuron disease. Mutations in 
the Cu/Zn superoxide dismutase (SOD1) gene are found in approximately 20% of 
familial forms of ALS which corresponds to 1-2% of all ALS cases and much of the 
pre-clinical work has been performed in mouse models containing mutations in SOD1 
[91]. SOD1 protein is located on the outer mitochondrial membrane and plays an 
important role in mitochondrial physiology [99]. Aggregated forms of mutant SOD1 
are found in sporadic and familial ALS, as well as in SOD1 transgenic models, in the 
form of cytoplasmic inclusions [100-102]. Whether these inclusions are also found in 
synapses has yet to be fully elucidated. Intriguingly, cultured motor neurons show a 
propensity for accumulating SOD1 aggregates when compared to cultured dorsal root 
ganglion or hippocampal neurons transfected with similar levels of mutant SOD1 
[103]. However, things are further complicated by the fact that these aggregates often 
include one or more other proteins known to play a role in ALS such as TAR DNA-
binding Protein 43 (TDP-43), ubiquitin, Fused in Sarcoma (FUS) and Sequestesome-1 
(p62/SQSTM1) [104].  Interestingly, the two RNA-binding proteins TDP-43 and FUS 
have been shown in cultured mouse neurons to traffic into dendritic spines and their 
synaptic levels significantly increase following neuronal activity [105, 106]. 
Therefore, given the high incidence of cytosolic protein aggregates it’s possible that 
sequestration of these important synaptic proteins away from their target site 
contributes to synaptic failure and loss. In support of this, it was recently shown in 
primary mouse neurons and human-derived motor neurons that ALS-associated 
mutations in TDP-43 led to reduced motility of TDP-43+ve mRNA granules along 
axons and a decrease in synapse-associated mRNA [107]. New protein synthesis is 
critical for long-lasting changes in synaptic remodelling and local synaptic mRNA 
trafficking and processing plays an important role. Therefore, disrupting either the 
temporal or spatial processing of synaptic mRNAs can have severely deleterious 
effects on neuronal function. 
 
Further evidence of synaptic disruption in ALS is the growing revelation of 
excitotoxicity in the disease. The strongest argument for a role of excitotoxicity in 
ALS is that the only drug capable of slowing disease progression in patients is 
riluzole, a suppressor of excitatory synaptic activity [108]. Furthermore, in human 
synaptoneurosomes preparations it has been found that glutamate re-uptake is 
significantly decreased compared to samples from control or non-ALS patients [109] 
and that CSF levels of glutamate are significantly higher in ALS patients [110, 111].  
Loss of glutamate transporters in ALS is found in both post-mortem tissue and rodent 
models [112, 113]. Motor neurons appear to be intrinsically vulnerable to 
excitotoxicity due to their high expression of Ca
2+
-permeable AMPA receptors and 
low expression of Ca
2+
 buffering proteins [114]. Therefore, subtle changes in their 
Ca
2+
 buffering capacity could render the postsynapse vulnerable to Ca
2+
-dependent 
excitotoxicity. In support of this idea it has been shown that mutated SOD1 can 
accumulate within vacuolated mitochondria [115], significantly disrupt mitochondrial 
function [116] and diminish the Ca
2+
-buffering capacity of these organelles [117]. 
Furthermore, corticostriatal plasticity is significantly altered in a mutated SOD1 
mouse model. In acute slices, tetanic stimulation (100 Hz, 1-s, 6-s interval) induced 
LTD in control slices but induced LTP in SOD1 mutants [118]. This synaptic 
alteration would shift the excitatory/inhibitory balance and transfer a physiological 
network into a hyperexcitable one. Altered physiology is not just limited to the brain 
however, as SOD1 transgenic mice also show alterations in spinal motor neuron 
activity. Electrically stimulated motor neurons from transgenic mice fired shorter 
action potentials in a higher frequency, due to decreased repolarization time [119]. 
Also, spinal motor neuron hyperexcitability appears to be a presymptomatic feature in 
SOD1 mouse models [120]. 
 
In summary, although it has been well established that neuromuscular synaptic loss is 
an early presymptomatic feature of ALS progression, the nature and source of the 
initiating toxic insult has yet to be convincingly described. Furthermore, the multi-
faceted pathology suggests that ALS is a multifactorial disorder, likely affecting 
synapses in numerous diverse ways, ultimately rendering them extremely vulnerable 
in the early stages of disease pathogenesis. 
 
Huntington’s Disease 
Huntington’s disease (HD) is caused by a trinucleotide (CAG) repeat expansion in the 
huntingtin gene, resulting in a polyglutamine expansion in the huntingtin protein. 
Patients exhibit classical movement disorders such as chorea and bradykinesia, 
cognitive deficits which progress into dementia and psychiatric symptoms such as 
depression [121]. These clinical features can be attributed to significant neuronal cell 
death in the striatum in the early stages (up to 95% loss of striatal medium spiny 
neurons), followed by more global brain atrophy [122]. Preceding neuronal death, 
alterations in spines and synapses are evident in both human post-mortem tissue and 
animal models of the disease [123]. In human post-mortem striatum, dendrites of 
medium-sized spiny neurons appear tortuous with recurved endings and exhibit a loss 
of spines [124, 125]. Similar findings are described in layer five of the prefrontal 
cortex [126]. Rodent models expressing mutant huntingtin transgenes (R6/1 HD mice) 
have revealed changes in dendritic spine density and anatomy, in HD-relevant brain 
regions [127]. Earlier attempts to generate rodent models of the disease involved 
intrastriatal injections of quinolinic acid, an endogenous NMDA receptor agonist, 
which produced neurodegenerative lesions that appeared neurochemically similar to 
those in human post-mortem tissue [128]. This suggested a prominent role for the 
excitatory glutamatergic system in HD pathogenesis. Furthermore, it has been shown 
in a mouse model of HD that an early increase in extrasynaptic NMDA receptor 
signalling may contribute to disease pathogenesis [129]. The authors revealed a 
significant increase in extrasynaptic NMDA-dependent currents, which coincided 
with increased extrasynaptic NMDA receptors. Environmental enrichment induces 
synapse formation and delays symptom onset and ameliorates symptoms in mouse 
models of HD, potentially by rescuing axonal transport of BDNF to the striatum and 
hippocampus [130-132]. Furthermore, it has been shown that wild-type huntingtin 
protein exists in postsynaptic membranes, binds PSD-95 [133, 134] and mutant 
protein can interfere with correct trafficking of postsynaptic receptors [135, 136]. 
Interestingly, specific loss of PSD-95 and GluR1-containing glutamatergic receptors 
occurs before the onset of spine loss [137], which suggests that spine loss is a result of 
synaptic dysfunction rather than a cause. As expected from the anatomical changes 
described, electrophysiological alterations are apparent in numerous model systems, 
with both resting and activity-dependent changes in neuronal physiology [138-140].  
 
Mitochondrial dysfunction is also evident in HD and appears to be a very early stage 
of pathogenesis, occurring presymptomatically [141, 142]. Striatal mitochondria 
containing mutant huntingtin have a reduced calcium uptake capacity than wild type 
cells [143]. Furthermore, mutant huntingtin binds to the mitochondrial outer 
membrane and directly lowers the threshold required for Ca
2+
-induced mitochondrial 
permeability [144]. Therefore, studies suggest that the dysfunction of mitochondrial 
Ca
2+
 handling may render HD neurons unable to cope with excessive neuronal 
activity, leading to early synaptic loss, followed by cell death.  
 
From the current literature, one can imagine a scenario in which mutated huntingtin 
initiates a cascade of disruption, starting with perturbed protein trafficking, synaptic 
dysfunction and spine loss, leading to network disconnection and ultimately neuronal 
death. 
 
Multiple Sclerosis 
Multiple sclerosis (MS) is a chronic, autoimmune disorder exhibiting inflammatory 
lesions in the CNS and subsequent axonal demyelination and neurodegeneration. The 
pathological hallmarks of the disease are sclerotic plaques, which represent the end-
point of a destructive process involving inflammation, demyelination, gliosis and 
axonal/neuronal death [145]. Clinically, neurodegeneration leads to progressive 
physical disability as neuronal networks and muscle control are lost [145]. Also, in 
addition to the sensory and motor deficits, up to 65% of MS patients present with 
cognitive deterioration [146]. The clinical course is complex, as the disease tends to 
wax and wane under the control of the inflammatory episodes with patients improving 
during remission. However, recovery from each relapse is usually incomplete and 
65% of patients will advance into a secondary progressive form of neurodegeneration 
[145]. 
 
Despite the well-described pathology, the exact order of events that lead to the 
formation of sclerotic plaques is hotly debatable. Recently, focus has centred on the 
role of inflammation-driven synapse alteration in MS pathogenesis. Using a non-
invasive imaging technique called Transcranial Magnetic Stimulation (TMS) to 
measure cortical activity in MS patients, it has been shown that intracortical 
facilitation is evident in MS patients [147] and that cortical hyperexcitability 
correlates with increased levels of pro-inflammatory cytokines in the CSF [148]. 
Furthermore, elevated levels of glutamate have been found in the CSF [149] and brain 
[150] of MS patients, pointing towards glutamate-induced excitotoxicity in the CNS. 
In support of this hypothesis, pharmacological blockade of glutamate receptors in 
rodent models of MS (experimental autoimmune encephalitis (EAE)), perturb disease 
progression and severity, reduce neurological deficits and decrease damage to axons 
and myelinating cells (oligodendrocytes), despite having no effect on CNS 
inflammation [151, 152]. Furthermore, in acute brain slices from EAE models it has 
been shown that LTP is enhanced and LTD is reduced, leading to an overall 
hyperexcitable environment, similar to the human cortex [153-155].  
 
In human post-mortem hippocampi, dramatic demyelination is observed [156, 157]. 
The loss of myelin associates with synaptic dysfunction, as although neuron number 
remains stable, synaptic density is significantly decreased [156, 157]. Interestingly. A 
role for the compliment system (C1q and C3) has been implicated in hippocampal 
synapse loss [157], which is a system thought to play an important role in 
supernumerary synapse elimination during development, but may be erroneously 
activated during disease [158]. Furthermore, in demyelinated hippocampi the levels of 
astrocytic glutamate uptake transporters EEAT1 and EEAT2 were significantly 
decreased [156], likely driving increased synaptic glutamate levels and subsequent 
synaptic breakdown. This is an important finding as approximately 50% of MS 
patients exhibit impaired long-term memory, a process that requires functional 
hippocampi [159]. Synapse loss has also very recently been documented in the cortex. 
In demyelinated areas of the post-mortem human insular and frontotemporal lobes, 
there were fewer intracortical axons and a dramatic decrease in spine numbers [160]. 
Interestingly, even in MS patients with normal appearing grey matter (without 
demyelination), spine density was significantly lower than control and not different to 
the densities in demyelinated patients [160]. Thus in the cortex, it appears synapse 
loss does not necessarily associate with demyelination. 
 
Excessive excitatory signalling could result from uncontrolled glutamate release, 
decreased glutamate clearance or increased postsynaptic expression of receptors. In 
fact, it appears all three may play a role. Glutamate transporters and metabolizing 
enzymes are lost from oligodendrocytes in and around active MS lesions and 
infiltrating immune cells express high levels of glutamate-synthesising enzymes, all 
contributing to the increased levels of synaptic glutamate and localised axon damage 
[161, 162]. Also, increased expression of glutamate receptors in glial cells and ectopic 
expression in axons is observed around active MS lesions [163, 164].  
 
Another condition in which network excitation can become excessive, is if inhibitory 
control is lost. Almost one quarter of neurons in the cortex are inhibitory [165] and 
they play an important role in regulating rhythmic firing across cortical networks. 
Numerous studies have shown that the inhibitory GABAergic system is disrupted in 
MS patients. It has been known for more than 30yrs that GABA levels in the CSF of 
MS patients are lower that controls [166] and around 10yrs ago it was shown by 
microarray and confirmed by RT-PCR and western blotting that many components of 
the GABAergic system were significantly down regulated in MS patients [167]. The 
authors reported a decrease in GABA receptor subunits, receptor associated proteins 
and presynaptic proteins involved in GABA synthesis. Also, they discovered that the 
cortical area covered in parvalbumin (Ca
2+
-binding protein highly expressed in a 
subpopulation of inhibitory cells) -positive cells and their processes was almost 30% 
lower in MS patients. These findings suggest that GABA release is lower in MS 
patients and the machinery required to send and receive inhibitory signals is 
significantly hindered in the MS brain. 
 
Another pathological feature described by Dutta et al. [167] in post-mortem MS 
motor cortex, was the breakdown of mitochondrial function. Interestingly, 
mitochondrial number and protein composition were the same in MS and control 
motor cortex preparations, however mitochondrial respiratory chain function was 
reduced by approximately 50% in MS samples [167]. Mitochondrial DNA (mtDNA) 
damage can induce significant mitochondrial dysfunction and in human MS cortical 
grey matter, there are extensive mtDNA deletions, leading to respiratory dysfunction 
[168]. In the EAE animal model of MS, mitochondrial breakdown and dysfunction 
appeared as early as three days after EAE sensitisation, long before leukocyte 
infiltration into the CNS [169]. Due to the mounting evidence in animal models and 
human tissue, mitochondrial dysfunction is becoming more appreciated as an 
important factor in MS pathogenesis [170], which may play a significant role in 
neuronal physiology, leading to synaptic breakdown. 
 
In summary, mounting evidence supports the supposition that changes in the neuronal 
milieu during inflammatory relapse leads to early synaptic dysfunction and a shift 
towards increased excitatory transmission, resulting in hyperexcitation and 
excitotoxic neurodegeneration. Furthermore, increased energy demands required to 
propagate signal transduction along demyelinated axons, coupled with decreased 
energy production due to dysfunctional mitochondria, leads to a virtual hypoxic state, 
further enforcing neurodegenerative processes. 
 
Normal cognitive ageing 
Despite the wealth of literature describing pathological changes in the diseased brain, 
we are yet to fully understand the changes that occur during normal ageing of the 
brain and it’s important to remember that age is a major risk factor for most 
neurodegenerative diseases. Normal cognitive ageing is likely influenced by a number 
of underlying factors and the term refers to age-related changes in cognition in the 
absence of any known neurologic disease [171]. Interestingly, this trait of age-related 
cognitive change is not restricted to humans and can be found in other aged species 
such as rodents and non-human primates [172]. Declarative and working memory are 
mediated by the hippocampus and dorsolateral prefrontal cortex respectively and are 
the most vulnerable cognitive processes in ageing [172]. Furthermore, it is known that 
regional coordination, required for higher order tasks, begins to breakdown during 
ageing [173] and is thought to be a result of alterations in the connections between 
these brain regions, driven by a deterioration of white matter physiology [174]. Post-
mortem, a number of structural changes are evident such as neuronal loss, white 
matter deterioration, gliosis, neurovascular changes and increased deposition of 
pigments and proteins inside cells [175]. Furthermore, glutamatergic signalling and 
glutamate homeostasis are disrupted in normal brain aging and this has knock-on 
deleterious effects on other neurotransmitter systems [176]. For example, the 
breakdown of important neurotransmitter systems such as the dopaminergic and 
serotonergic systems appears to be an age-dependent process [177, 178]. However, 
despite all these diverse changes it has been frequently shown that synaptic health is 
essential in maintaining cognitive performance in older age and it is synaptic density, 
not neuronal loss, that associates most strongly with age-related cognitive decline 
[172].  
 
Using genome-scale microarrays it has been shown that genes involved in the 
regulation of synaptic function are significantly down regulated in aged human brain 
[179, 180]. Also, genetic variability within genes coding for postsynaptic proteins 
preferentially associates with the inherent variability in general intelligence [181]. 
Evidence supporting an age-dependent change in synapses is not merely genetic. In 
non-human primates there is a significant age-related decrease in volume of the 
dorsolateral prefrontal cortex, which is not caused by neuronal loss but associates 
with a dramatic loss of glutamatergic, axospinous synapses [182]. Furthermore, this 
synaptic loss (specifically in cortical layer 3) correlates with the degree of cognitive 
decline in the aged animals. This is similar to human ageing studies that have shown 
an association between high presynaptic protein levels and lower odds of dementia 
diagnosis in later life [183]. Also, human post-mortem studies have revealed a 
decrease in synaptic density in an array of cortical regions, including the prefrontal 
cortex, without changes in neuron number [184-187]. Thus it appears that synaptic 
loss is a feature of normal brain ageing across a variety of distinct species, but what 
drives or initiates this process? Interestingly, some genes involved in vital processes 
such as mitochondrial function, immune regulation and inherent stress responses are 
changed in an age-dependent manner and these changes are evolutionarily conserved 
throughout the animal kingdom from humans to nematode worms [188]. Thus it 
appears that the brain ages in a similar way across species and that common factors 
likely drive synaptic loss. For example, genes encoding mitochondrial proteins are 
decreased across species in aged individuals [180] and studies have shown significant 
mitochondrial dysfunction in many animal models of ageing [189]. Human 
mitochondrial DNA deletions increase with age [190], and interestingly deletions 
were common in the cortex but largely absent from the cerebellum. This may partly 
explain the more prominent cognitive decline associated with ageing. In rodents, 
mitochondrial enzyme activity correlates with neurological performance and median 
life span and ageing associates with increased mitochondrial dysfunction and fragility 
[189]. Furthermore, in non-human primates, mitochondrial number and morphology 
in the presynapse correlates with performance in working memory tasks, which 
declines with age [191].  
 
As the brain ages, postmitotic neurons that have worked diligently for decades, begin 
to tire. Underlying degeneration of DNA repair mechanisms and mitochondrial 
function begin to take their toll on neuronal physiology and the critical points of 
contact and communication between cells (synapses) start to breakdown. As synapses 
are lost during ageing, there is an inevitable change in neuronal electrophysiology, 
and for a long time it has been known that aged animals showing a brain region 
specific decrease in LTP [192-195]. Also, as Ca
2+
 homeostasis alters, likely due to 
dysfunction in Ca
2+
-buffering organelles, synaptic plasticity favours LTD induction 
rather than LTP [196]. Synapse loss and physiological alterations occur as a prelude 
to neuronal loss and synapse loss correlates with early cognitive change. However 
given the inherent malleability of spines and synapses, this could provide a 
therapeutic opportunity for slowing the progression of not only ageing but also some 
neurodegenerative diseases, such as those described above.  
 
Current and potential therapies in neurodegenerative disease 
During neurodegenerative disease, the processes regulating synaptic signalling and 
adaptation are hindered and as a result, physiological plasticity is lost. However, by 
pharmacologically altering synaptic function to regain the delicate balance of synaptic 
physiology, we could potentially prevent synaptic loss and even induce synaptic 
growth. This is critically important given that synapse loss often occurs in the early 
prodromal phases before overt and irreversible neuron death has occurred. This would 
considerably widen the therapeutic window for such disorders, providing aid to 
millions of patients around the world.  
 
Most of the treatments currently licenced for neurodegenerative diseases act by 
boosting diminishing synaptic function or blocking excessive synaptic activity in 
overactive circuits. For example, acetylcholinesterase inhibitors are used to prevent 
the breakdown of the neurotransmitter acetylcholine in the brain and thus boost 
cholinergic signalling. These treatments are based on the early Cholinergic 
Hypothesis of Alzheimer’s pathogenesis from the observations in the 1970s that 
cholinergic neurons are lost early in the disease process [197]. While these treatments 
ameliorate symptoms to some extent in some stages of the disease, they do not slow 
progression because the loss of cholinergic neurons is not the primary cause of the 
disease.  One example of a cholinesterase inhibitor is Donepezil which is used in AD 
to enhance the signalling capacity of the degenerating cholinergic cells of the basal 
forebrain, having a small positive effect on cognition and daily living in patients with 
mild-to-moderate AD [198]. Rivastigmine (cholinesterase inhibitor) is the favoured 
treatment for DLB and has produced significant improvement in patients’ 
hallucinations, cognition and behavioural changes in DLB patients over a 96-week 
treatment period [199], but again this symptomatic relief does not alter disease 
progression. In PD, the treatments are more effective because loss of a single 
neurotransmitter, dopamine, does appear to drive the disease process. Levodopa is 
currently the most effective treatment for the motor symptoms of PD and is used in 
combination with carbidopa, which inhibits the peripheral breakdown of levodopa 
allowing more drug to enter the brain [200]. Levodopa counteracts the loss of 
dopamine producing neurons in the substantia nigra by replacing dopamine in the 
brain. Another common therapeutic approach is to block excessive excitatory 
signalling. Memantine is a non-competitive NMDA receptor antagonist that appears 
to have specificity for open, extrasynaptic channels thus preventing glutamatergic 
excitotoxicity but leaving normal synaptic function unhindered, however the exact 
mechanism of action is still debated [201, 202].  Memantine can enhance cognition in 
patients with moderate-to-severe dementia [203]. Riluzole is used as a 
neuroprotective drug in ALS. It has many effects on neuronal physiology and 
certainly inhibits neurotransmitter release and glutamate receptors, leading to the 
hypothesis that it’s effects in ALS are to dampen excitotoxicity [204]. Interestingly, 
Riluzole is currently in Phase II trials as a combination therapy with two other drugs 
for treating MS [205-207]. Tetrabenazine has an unknown mode of action, but is 
believed to deplete levels of monoamines in the presynapse, by inhibiting vesicular 
monoamine transporter 2 (VMAT2) and is effective at controlling chorea in HD 
[208].  
 
The number of licensed drugs for these disorders may seem encouraging, however 
none of these can be cured and most of the drugs have very limited effect if any on 
slowing disease progression. In fact, despite Riluzole being the only available 
medication with any proven effect in ALS, it can only prolong life by around two to 
three months [209], thus new therapeutics and novel approaches are desperately 
needed. One approach being pursued in a number of diseases is gene therapy. Gene 
therapy trials have already been run for PD, however despite positive safety results 
the trials have yet to yield clinical efficacy [210]. Encouraging success in the 
treatment of the motor neuron disease, spinal muscular atrophy (SMA) has inspired 
hope in the field of ALS, however given the genetic heterogeneity of the disease, it 
will likely not prove a viable therapy available for all patients [211]. Gene therapy 
approaches are also being considered for HD [212], however the fine balance of 
huntingtin levels will be crucial as conditional removal of the gene in adult mice led 
to neurodegeneration [213]. While gene therapy represents an exciting potential 
approach for some neurological disorders, vector properties, cellular targeting and 
precise control over transgene expression remain considerable hurdles to be cleared 
before widespread use [214]. Another approach that has reached clinical trial stage for 
AD, PD, DLB and HD is the specific targeting of the pathological proteins (amyloid-
 tau, α-synuclein and huntingtin) associated with the disease and aiding clearance 
from the brain. These include increasing protein clearance by enhancing proteasomal 
function, dampening post-translational modifications associated with pathological 
forms of protein and preventing protein aggregation [121, 215]. However, this 
approach should be treated with extreme caution and lessons must be learned from 
AD in which trials aimed at clearing toxic amyloid from the brain have so far all 
failed to reach their primary clinical endpoints [216], highlighting the difficulty of 
translational medicine in the field of neurodegenerative diseases. 
 
It is clear that new medications are required for neurodegenerative disease, potentially 
to prevent or reverse synapse loss.  One potentially interesting novel approach is the 
targeting of neuronal extracellular matrix components. The formation of perineuronal 
nets (PNNs) is thought to be a critical stage of neurodevelopment and results in the 
formation of neuroprotective barriers around cells, and helps stabilise mature synaptic 
contacts [217]. Interestingly, in AD it appears that PNNs are lost in plaque cores and 
cells that retain these nets are devoid of tau pathology, despite being surrounded by 
severely affected cells [218]. Furthermore, cultured neurons with an intact PNN were 
protected against treatment with exogenous Aβ1-42, whereas cells without a PNN, 
degenerated [219]. Many of the extracellular matrix molecules are found at synapses, 
although their exact role in synaptic physiology and whether they are 
synaptoprotective has yet to be elucidated [217]. However, this interesting therapeutic 
avenue is not without it’s paradoxes. Recent data suggests that digesting PNNs with 
chondroitinase actually reverses memory deficits in mouse tauopathies by specifically 
aiding synaptic plasticity, without altering pathological load [220]. Therefore more 
research is required into the role(s) of the extracellular matrix in disease pathogenesis, 
however it is interesting to consider the possibility of altering the PNN defences 
around synapses to inhibit or even reverse synapse loss in neurodegenerative disease. 
 
Conclusion 
While the neurodegenerative diseases mentioned above appear distinct in their 
causative factors and end-point pathologies, examining their early-stage pathogenesis 
reveals a coalescent point at the synapse (see Table 1). Our understanding of synaptic 
structure has expanded immeasurably since the beautiful observations and drawings 
of dendritic spines by Ramon Cajal in the 19
th
 century. Modern technology now 
allows us to probe neuronal and network function with a flash of light [221] and to 
visualise numerous proteins within a 3-dimension nanometre scale, at individually 
identified synapses  [222]. While these are amazing advances for academic research, 
most are only applicable to transgenic model systems and our ability to perform such 
experiments in living patients is a long way off. If such techniques were available to 
assess synaptic function in living patients, neurodegenerative diseases could be 
diagnosed at prodromal stages. 
 
Currently, most neurodegenerative diseases have their own distinct therapeutic 
programmes for tackling the disease, with varying levels of successes. Most drugs 
treat the symptoms of the disease, but a better approach may be to combine efforts in 
an attempt to identify common factors and focus on preventing or delaying disease 
pathogenesis. As described above, some medications are useful for more than one 
disease, which suggests common features must play a part in disease pathogenesis. 
With greater collaboration between researchers working on different diseases, both in 
and outside the clinic, our hopes of finding novel synaptoprotective therapies can be 
achieved. 
 
 
Table 1: Summary of common disease-related synaptic pathologies 
Disease Synapse loss 
Synaptic 
accumulation 
Disrupted 
synaptic 
Disrupted 
mitochondria 
Alterations 
in synaptic 
of disease-
related 
protein 
plasticity machinery 
AD 
Early synapse 
loss even before 
amyloid plaque 
formation and 
loss correlates 
with cognitive 
decline 
(18, 20, 21, 23, 
41) 
Amyloid-β and 
pTau 
(21, 24, 44-47) 
Disrupted 
LTP and 
enhanced 
LTD 
(26-30, 33, 
48, 49) 
Amyloid-β 
induces 
mitochondrial 
dysfunction and 
pTau disrupts 
mitochondrial 
trafficking 
(41, 42, 47, 50, 
51) 
Disrupted 
trafficking of 
synaptic 
receptors 
(33, 37, 38, 40, 
48, 49) 
PD 
Early loss of 
synapses in the 
striatum 
(7, 70-72) 
α-synuclein 
(73-75) 
Disrupted 
LTP 
(80, 81) 
PD genetic risk 
factors are 
associated with 
mitochondrial 
dysfunction 
(85-89) 
Presynaptic 
disruption of 
numerous 
neurotransmitter 
systems 
(76-79) 
DLB 
Loss of 
hippocampal 
and cortical 
synapses  
(74, 75) 
α-synuclein 
(74, 75) 
Disrupted 
LTP 
(80, 81) 
Mitochondria 
accumulate and 
breakdown 
around Lewy 
bodies 
(86, 87, 90) 
α-synuclein-
induced 
internalisation 
of synaptic 
receptors 
(80-82) 
MND 
Early synapse 
loss in the 
motor and 
sensorimotor 
cortices and 
onto lower 
motor neurons 
of the spinal 
cord 
(92-96) 
Unknown 
Increased 
excitability 
and 
enhanced 
LTP 
(118-120) 
SOD1 is a 
mitochondrial 
protein, when 
mutated it 
accumulates in 
mitochondria 
and disrupts 
their function 
(91, 99, 115-
117) 
Decreased 
glutamate 
clearance in 
motor cortex 
and spinal cord 
(109-113) 
HD 
Presymptomatic 
loss of synapses 
and spines 
(123-127) 
Huntingtin 
(133-137) 
Disrupted 
LTP 
(138-140) 
Mitochondrial 
calcium handling 
defects occur 
early in disease 
pathogenesis 
(141-144) 
Disrupted 
trafficking of 
synaptic 
receptors 
(135, 136) 
MS 
MS cortex and 
demyelinated 
hippocampi 
contain less 
synapses 
(156, 157, 160) 
Unknown 
Disrupted 
LTD and 
enhanced 
LTP 
(147, 148, 
153-155) 
Mitochondrial 
dysfunction 
occur early in 
mouse models of 
MS and defects 
are commonly 
found in patients 
(167-170) 
Altered 
glutamate 
release and 
uptake  
(147-152, 156, 
161-164) 
Ageing 
Age-dependent 
synapse loss 
correlates with 
cognitive 
decline 
(172, 179-187) 
Unknown 
Disrupted 
LTP and 
enhanced 
LTD 
(192-195) 
Mitochondrial 
dysfunction 
increases with 
age 
(180, 189-191) 
Age-related 
decline in 
numerous 
neurotransmitter 
systems  
(176-178) 
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Figure Legends 
Figure 1: Synaptic structure  
A. Neurons within a network frequently communicate by passing excitatory messages 
from one cell (pink) to another (blue) at small compartments known as synapses. 
Excitatory synapses often occur between a presynaptic axon terminal and a 
postsynaptic dendritic spine (lower panel) and this is known as an axospinous 
synapse. B. Electron micrograph from the mouse nucleus accumbens showing an 
axospinous synapse. The presynaptic terminal (pink) contains the machinery required 
to release small packets of neurotransmitter inside synaptic vesicles (s.v.) which when 
released, cross the synaptic cleft and act on the next cell (blue). Synapses require a lot 
of energy and two small mitochondria (m) can be seen inside the presynaptic 
terminal. The postsynaptic cell contains a clearly identifiable spine, protruding from 
the dendritic shaft. The spine head receives the synaptic message from the presynaptic 
cell at an electron dense accumulation of proteins known as the PSD (within the red 
arrowheads). Note the dendritic mitochondria (m) in close proximity to the spine. 
Scale bar = 100nm. C. Diagram highlighting a select few of the presynaptic and 
postsynaptic components of the synapse. Presynaptically, the microtubule-binding 
protein Tau can be found bound to microtubules and Ca
2+
-permeable ion channels are 
located on the terminal’s plasma membrane. Synaptic vesicles are presynaptic and 
contain α-synuclein in the membrane and neurotransmitters within their lumen. 
Neurexins protrude into the synaptic cleft, looking for their postsynaptic neuroligin 
partners and help hold the synapse in place. Postsynaptically, ionotropic 
glutamatergic receptors such as NMDA and AMPA receptors are found directly 
opposing the presynapse. These are held in place by scaffolding proteins such as 
PSD95 and SAP102, which form an integral part of the PSD. Other important 
scaffolding molecules such as Homer, GKAP and Shank combine to hold 
metabotropic glutamate receptors such as mGluR5 in place, in perisynaptic regions. 
Spine architecture is maintained by important structural proteins such as F-actin, 
which are found in the spine neck and base of the spine head. It is believed that 
interactions between Shank and cortactin allow synaptic changes to influence spine 
dynamics, via alterations in F-actin. 
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